Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

ations management, healthcare utilization and organizational planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A. in biology from the University of Delaware and an M.B.A. from the University of Connecticut.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company contact: Investor contact:

Paul Schneider Rhonda Chiger

TorreyPines Therapeutics, Inc. Rx Communications Group

858-623-5665
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... , ... VetStem Biopharma will be offering weekly private guided tours of our ... , The tour and course will be given every Wednesday at 6pm to local ... Staff members are welcome to attend with their veterinarian as well. Participants will be ...
(Date:7/28/2015)... , July 28, 2015 BioStructures, LLC, ... has hit a milestone of 4,000 implantations of ... 510(k) cleared in early 2014 as a bone ... spine fusion procedures.  This is a distinguished status ... than 6% of new synthetic products have received ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... ... Production of high tenacity filament yarn of viscose rayon (excluding sewing thread) demonstrated ... surpassed the EUR 106 million mark (in value terms) in 2013, while it stood ... while Italy is a key consumer. , The high tenacity filament yarn of ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... its revolutionary Trusted LASIK Surgeons directory service and website ... resource for consumers seeking to improve their vision. What ... unique screening process ensuring that only those who are ... eye surgery in the United States are listed. Refractive ...
... Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 million to ... and to support initial research into,three new vaccines for ... funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides essential funding ... WAVA core operations during ...
... Fuld & Company today announced that Wayne Rosenkrans, ... specializing in strategic gaming for the pharmaceutical and healthcare ... "We are excited to have Dr. Rosenkrans join ... accomplishment in the global pharmaceutical industry; government and academia ...
Cached Biology Technology:Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 2Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 3Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 4Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 5Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 6Hawaii LASIK Eye Surgery Expert Dr. John D. Olkowski Qualifies and Lists with Trusted LASIK Surgeons 7Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services 2
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... Identity science takes a giant leap forward with ... at the new $1.5 million per year Pedo-Biometrics Research ... ID, an Ottawa, Canada, company currently relocating operations to ... a variety of identification uses, from security to detecting ...
... a threatened species, population, or genotype to an area ... response to the threat of extinction resulting from climate ... BioScience by Mark W. Schwartz and his ... Working Group, an interdisciplinary group of scientists, researchers, and ...
... obesity and vitamin D deficiency may put people at even ... to new research from the Drexel University School of Public ... Care. Insulin resistance is a major risk factor for ... and is the seventh leading cause of death in the ...
Cached Biology News:Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 2Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 3Developing policy on moving threatened species called 'a grand challenge for conservation' 2Obesity plus low vitamin D may add up to a greater risk of diabetes 2
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
QCPN...
... new MALDI O-TOF creates a new category ... orthogonal platform that has been licensed to ... of Manitoba. , As the first single ... and collisional cooling, the prOTOF 2000 represents ...
Biology Products: